

## **Biotechnology Stock News: Natural Anti Inflammatory Drug Products Developer Makes Major Acquisitions**

*Biotechnology developer of natural anti inflammatory drugs, Metabolic Research Inc. (Stock Symbol: MTBR), acquires biotechnology products marketing company and proprietary technologies*

May 30, 2007 (FPRC) -- Las Vegas, Nevada — In biotechnology stock news, developer of natural anti inflammatory pharmaceutical products, Metabolic Research Inc. (Stock Symbol MTBR), announces two significant acquisitions.

You can visit <http://www.princetonresearch.com/mtbr.htm> for stock quotes and more information.

On May 23 Metabolic Research (MTBR corporate web site: [www.metabolicresearchinc.com](http://www.metabolicresearchinc.com)) acquired IDZIN, Inc. a biotechnology marketing company with proprietary software, strong Internet presence and logistics facilities. IDZIN has profitable cash flow and they will become a wholly owned subsidiary of Metabolic Research (MTBR). In addition IDZIN has established relationships with decision makers at target market companies, and they have developed a marketing system that addresses Metabolic's primary target markets.

"This transaction will further accelerate our profitable entry into the market," said Dr. David Summers, Chairman and CEO. "The IDZIN customer base will propel sales of our line of dynamic state-of-the-art, natural, bio-identical, pharmaceutical-grade products.

On May 16 Metabolic Research (MTBR) acquired principal assets relating to metabolically engineered drug development, formulas, prototypes, packaging design and marketing rights from Partners in Science Holdings, Inc. The acquisition was completed through an "all stock" transaction utilizing restricted common shares of the Company.

Metabolic Research plans to utilize this technology to further its research and development of a new form of natural anti-inflammatory and analgesic products, both pharmaceuticals and nutraceuticals, for the treatment of arthritis and other inflammatory diseases.

Included in the purchase are 15 product formulations, branding for four trademarks/trade names, six provisional patent applications, two technologies ready for patent filing, three contract executives, and one marketing contract, all of which should enable MTBR to enter the market during the current quarter.

"This transaction should accelerate Metabolic Research's path to profitability. This acquisition should prove to be the catalyst we need to quickly move from the R&D phase into one where we realize increasing revenues and profits, thus building long-term equity for our shareholders," says Dr. David Summers, D.Sc., Ph.D., Chief Executive Officer of Metabolic Research, Inc.

About Metabolic Research, Inc.:

Changing the way drugs are grown, Metabolic Research (MTBR) is a biotechnology company developing a new form of pharmaceutical grade non-synthetic pharmaceuticals aimed to safely and

effectively treat arthritis, heart disease and metabolic and inflammatory diseases. MRI's proprietary process is based on "growing" drugs by using natural metabolic processes of plants or fungus rather than chemical synthesis used by traditional pharmaceutical companies.

Metabolic Research, Inc. has recently acquired a license for two provisional patents "Composition and Method of Producing Endogenous Therapeutic Anti-Inflammatory Eiconasids and their Metabolites by Exogenous or Oral Means," and "Method and Process for Producing Anti-inflammatory Products from Fungi."

MRI's short-term game plan calls for using these patents to develop a natural drug to effectively treat arthritis.

MRI has just teamed up in a strategic alliance, one of the goals of which is to effectively develop a natural drug for cancer treatment.

This press release may include "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations reflected in such forward-looking statements will prove to have been correct. The Company's actual results could differ materially from those anticipated in the forward-looking statements.

**Contact Information**

For more information contact Mike King of Princeton Research (<http://www.princetonresearch.com>)  
702 650-3000

**Keywords**

[biotechnology](#)

[stocks](#)

[Anti Inflammatory](#)

You can read this press release online [here](#)